# A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy

> **NCT01209689** · PHASE3 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 113 (actual)

## Conditions studied

- Spondylitis, Ankylosing

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01209689
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 113 (ACTUAL)
- **Why stopped:** Clinical development program terminated due to failure to achieve efficacy
- **Last updated:** 2013-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01209689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01209689, "A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01209689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*